GSK plc with ticker (LON:GSK) now has a potential upside of .1% according to Barclays.
Barclays set a target price of 1,800 GBX for the company, which when compared to the GSK plc share price of 1,798 GBX at opening today (20/07/2022) indicates a potential upside of .1%. Trading has ranged between 1,704 (52 week low) and 3,408 (52 week high) with an average of 10,506,224 shares exchanging hands daily. The market capitalisation at the time of writing is £72,613,451,208.
GSK plc, formerly GlaxoSmithKline PLC is a global healthcare company. The Company is focused to improve the quality of human life by helping people. The Company operates through three core businesses: Pharmaceuticals, Vaccines and Consumer Healthcare. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency viruses (HIV), immuno-inflammation and oncology. It also focuses on immunology, human genetics, and advanced technologies to deliver transformational new medicines for patients. The Company’s research and development focuses on developing vaccines against infectious diseases that combine high medical needs and market potential. The Company’s Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands for oral health, pain relief, cold, flu and allergy, digestive health, and vitamins, minerals and supplements. It provides prescription medicines, vaccines, and consumer healthcare products.
GSK plc .1% potential upside indicated by Barclays
- Written by: Charlotte Edwards
Find more news, interviews, share price & company profile here for:
GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates.
GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns.
GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results.
GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe.
GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates.
GSK's Shingrix aims for FDA-approved prefilled syringe to simplify shingles vaccination, enhancing convenience for healthcare providers.
